AR052191A1 - Metodo de tratamiento - Google Patents

Metodo de tratamiento

Info

Publication number
AR052191A1
AR052191A1 ARP060100058A ARP060100058A AR052191A1 AR 052191 A1 AR052191 A1 AR 052191A1 AR P060100058 A ARP060100058 A AR P060100058A AR P060100058 A ARP060100058 A AR P060100058A AR 052191 A1 AR052191 A1 AR 052191A1
Authority
AR
Argentina
Prior art keywords
disorders
related disorders
substance
pharmaceutically acceptable
limited
Prior art date
Application number
ARP060100058A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR052191A1 publication Critical patent/AR052191A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método para tratar al menos un síntoma o afeccion asociado con, aunque sin limitarse a: 1) Trastornos relacionados con sustancias incluyendo aunque sin limitarse a Dependencia de Sustancias, Abuso de Sustancias, Intoxicacion por Sustancias, Abstinencia de Sustancias, Trastornos Relacionados con el Alcohol, Trastornos Relacionados con Anfetaminas ( o Tipo Anfetaminas), Trastornos Relacionados con la Cafeína, Trastornos Relacionados con el Cannabis, Trastornos Relacionados con la Cocaína, Trastornos Relacionados con Alucinogenos, Trastornos relacionados con Inhalantes, Trastornos relacionados con la Nicotina, Trastornos relacionados con Opioides, Trastornos relacionados con Fenciclidina ( o del Tipo de la Fenciclidina) y Trastornos relacionados con Sedantes, Hipnoticos o Ansiolíticos; 2) Trastornos de Déficit de Atencion y Comportamiento Disruptivo; 3) Trastornos de la Alimentacion; 4) Trastornos de Personalidad que incluyen, aunque sin limitarse a Trastorno de la Personalidad Obsesivo-Compulsivo; 5) Trastornos de Control de Impulsos, que comprende la administracion de una cantidad eficaz de formula (1) o su sal farmacéuticamente aceptable. En otro aspecto de la presente se proporciona una composicion farmacéutica que comprende una cantidad eficaz de formula (1) o su sal farmacéuticamente aceptable y por lo menos un portador o diluyente farmacéuticamente aceptable.
ARP060100058A 2005-01-07 2006-01-06 Metodo de tratamiento AR052191A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US64226205P 2005-01-07 2005-01-07
US73786405P 2005-11-18 2005-11-18
US73786505P 2005-11-18 2005-11-18
US73788705P 2005-11-18 2005-11-18

Publications (1)

Publication Number Publication Date
AR052191A1 true AR052191A1 (es) 2007-03-07

Family

ID=36647771

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100058A AR052191A1 (es) 2005-01-07 2006-01-06 Metodo de tratamiento

Country Status (6)

Country Link
EP (1) EP1838325A1 (es)
JP (1) JP2008526839A (es)
AR (1) AR052191A1 (es)
TW (1) TW200640466A (es)
UY (1) UY29326A1 (es)
WO (1) WO2006073360A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009516708A (ja) * 2005-11-18 2009-04-23 アストラゼネカ・アクチエボラーグ 液体製剤
PE20110029A1 (es) 2008-06-20 2011-02-11 Astrazeneca Ab Derivados de dibenzotiazepina
WO2010085976A1 (en) * 2009-01-30 2010-08-05 F.I.S. Fabbrica Italiana Sintetici S.P.A. Process for the synthesis of quetiapine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US7071133B2 (en) * 1993-11-16 2006-07-04 Ppg Industries Ohio, Inc. Colored glass compositions and-automotive vision panels with-reduced transmitted-color shift
US5602124A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. 5-HT2 receptor ligands
SE0003126D0 (sv) * 2000-09-05 2000-09-05 Astrazeneca Ab Method of treatment
ES2284830T3 (es) * 2001-02-06 2007-11-16 Astrazeneca Ab Uso de quetiapina para el tratamiento de la cocaina.
WO2004034996A2 (en) * 2002-10-18 2004-04-29 Massachusetts Mental Health Institute TREATING ALCOHOL AND OR SUBSTANCE ABUSE BY ANTAGONIZING α 2 ADRENERGIC RECEPTORS WITH WEAK DOPAMINE BLOCKING
AU2004253334A1 (en) * 2003-07-02 2005-01-13 Astrazeneca Ab Metabolite of quetiapine
CA2547652A1 (en) * 2003-12-04 2005-06-16 The Research Foundation Of The City University Of New York Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal
CN101962369A (zh) * 2003-12-22 2011-02-02 阿卡蒂亚药品公司 氨基取代的二芳基[a,d]环庚烯类似物作为毒蕈碱激动剂的用途及神经精神疾病的治疗方法
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic

Also Published As

Publication number Publication date
TW200640466A (en) 2006-12-01
EP1838325A1 (en) 2007-10-03
UY29326A1 (es) 2006-08-31
WO2006073360A1 (en) 2006-07-13
JP2008526839A (ja) 2008-07-24

Similar Documents

Publication Publication Date Title
Bhutada et al. Reversal by quercetin of corticotrophin releasing factor induced anxiety-and depression-like effect in mice
Zeni et al. Antidepressant-like and neuroprotective effects of Aloysia gratissima: investigation of involvement of L-arginine-nitric oxide-cyclic guanosine monophosphate pathway
WO2006053049A3 (en) Herbal composition phy906 and its use in chemotherapy
BR0210711A (pt) Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto
BRPI0607017B8 (pt) composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
BRPI0519181A2 (pt) composto ou um sal farmaceuticamente aceitÁvel do mesmo, processo para preparar o mesmo, composiÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel do mesmo, e, mÉtodos para produzir um efeito inibitàrio de b-raf em um animal de sangue quente, para produzir um efeito anti-cÂncer em um animal de sangue quente e para tratar uma doenÇa em um animal de sangue quente
ATE551060T1 (de) Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen
AR055095A1 (es) Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c
AR065120A1 (es) Compuesto de aril pirazol azoespirodecanona, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende
BRPI0411906A (pt) compostos, processo para a sua preparação, composições farmacêuticas que compreendem os mesmos, método para tratar ou prevenir uma enfermidade mediada pela ativação da enzima de sintase de glicogênio, e utilização dos compostos
WO2001066123A3 (en) Composition consisting of phy906 and chemotherapeutic agents
BR0317358A (pt) Composto de pirrolopiridazina, processo para sua preparação, composição farmacêutica contendo o mesmo, método de prevenção ou tratamento de doenças contendo o mesmo e seu uso
WO2008036682A3 (en) Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
BRPI0511874A (pt) derivados da pirrolopiridina
AR062068A1 (es) Sal tartrato de(7)s-7-[(5-fluoro-2-metil-bencil)oxi]-2-[(2r)-2-metilpiperazin-il]-6,7-dihidro-5h-ciclopenta[b]piridina, composiciones farmaceuticas que la contienen, y usos en trastornos asociados fundamentalmente al scn
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
Martin Therapeutic potential of KELEA activated water
Ebrahimzadeh et al. Anticonvulsant activity of Hypericum scabrum L.; possible mechanism involved
BRPI0409796A (pt) uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina
AR052191A1 (es) Metodo de tratamiento
Segura-Aguilar et al. Neurotoxins and neurotoxicity mechanisms. An overview
Guo et al. M9, a novel region of amino‐Nogo‐A, attenuates cerebral ischemic injury by inhibiting NADPH oxidase‐derived superoxide production in mice
Morshedi et al. The effect of artemisia sieberi besser on infkammatory and neurogenic pain in mice
GT200400068A (es) Derivados de 3-azabiciclo[3.2.1]octano

Legal Events

Date Code Title Description
FA Abandonment or withdrawal